Pengrowth Announces Plan to Reduce Outstanding Debt by

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
89
Pengrowth Announces Plan to Reduce Outstanding Debt by $530MM Through Retirement of $127MM of Convertible Debentures and the Prepayment of US $300MM of the 6.35% Senior Notes Due July 26, 2017

CALGARY, ALBERTA--(Marketwired - Feb. 21, 2017) - Pengrowth Energy Corporation (TSX:PGF)(NYSE:PGH) is pleased to announce its plan to reduce its outstanding debt through the use of existing cash on hand. Following the closing of the four percent non-convertible gross overriding royalty on Lindbergh on January 6, 2017, the Company's cash position was approximately $530 million.

Pengrowth intends to use the cash on hand to retire the $127 million of convertible debentures, on maturity on March 31, 2017 and to use the remaining cash to pre-pay US $300 million principal amount outstanding of the US $400 million 6.35% senior notes maturing July 26, 2017 (the "6.35% Senior Notes"). The Company has given notice to holders of the 6.35% Senior Notes of its plan to prepay 75 percent of the notes plus accrued interest and make whole payments pursuant to the terms of the Note Purchase Agreements. The prepayment will be made on a pro-rata basis on March 30, 2017.

Following these payments, the Company expects its pro-forma debt to be reduced to approximately $1.1 billion and comprised entirely of senior term notes.

Pengrowth continues to seek out opportunities to further reduce its outstanding debt and improve its balance sheet, including through the disposition of assets. The Company intends to apply the proceeds from potential asset divestitures, if any, to the prepayment of the remaining outstanding balance of the 6.35% Senior Notes, as well as proceeding to prepay the remaining notes outstanding in order of maturity. The Corporation is also continuing with ongoing negotiations with its remaining noteholders and bank lenders in an effort to obtain covenant relaxation.

About Pengrowth :

Pengrowth Energy Corporation is an intermediate Canadian producer of oil and natural gas, headquartered in Calgary, Alberta. Pengrowth's assets include the Lindbergh thermal oil, Cardium light oil, Swan Hills light oil and the Groundbirch and Bernadet Montney gas projects. Pengrowth's shares trade on both the Toronto Stock Exchange under the symbol "PGF" and on the New York Stock Exchange under the symbol "PGH".

PENGROWTH ENERGY CORPORATION

Derek Evans, President and Chief Executive Officer

For further information about Pengrowth, please visit our website www.pengrowth.com or contact: Investor Relations, E-mail: investorrelations@pengrowth.com

Caution Regarding Forward Looking Information:

This press release contains forward-looking statements within the meaning of securities laws, including the "safe harbour" provisions of the Canadian securities legislation and the United States Private Securities Litigation Reform Act of 1995. Forward-looking information is often, but not always, identified by the use of words such as "anticipate", "believe", "expect", "plan", "intend", "forecast", "target", "project", "guidance", "may", "will", "should", "could", "estimate", "predict" or similar words suggesting future outcomes or language suggesting an outlook. Forward-looking statements in this press release include, but are not limited to: pre-payment of US $300 million of the 6.35% Senior Notes; plans to retire outstanding convertible debentures at maturity; pro-forma debt; asset sales initiatives and using the proceeds from divestitures to prepay the remaining outstanding balance of the 6.35% Senior Notes, as well as prepay principal outstanding balances on remaining senior notes as well as ongoing negotiations with noteholders and bank lenders regarding covenant relaxation. Forward-looking statements and information are based on current beliefs as well as assumptions made by and information currently available to Pengrowth concerning anticipated financial performance, business prospects, strategies and regulatory developments. Although management considers these assumptions to be reasonable based on information currently available to it, they may prove to be incorrect.

By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks that predictions, forecasts, projections and other forward-looking statements will not be achieved. We caution readers not to place undue reliance on these statements as a number of important factors could cause the actual results to differ materially from the beliefs, plans, objectives, expectations and anticipations, estimates and intentions expressed in such forward-looking statements. These factors include, but are not limited to: changes in general economic, market and business conditions; the volatility of oil and gas prices; fluctuations in production and development costs and capital expenditures; the imprecision of reserve estimates and estimates of recoverable quantities of oil, natural gas and liquids; Pengrowth's ability to replace and expand oil and gas reserves; geological, technical, drilling and processing problems and other difficulties in producing reserves; environmental claims and liabilities; incorrect assessments of value when making acquisitions; increases in debt service charges; the loss of key personnel; the marketability of production; defaults by third party operators; unforeseen title defects; fluctuations in foreign currency and exchange rates; fluctuations in interest rates; inadequate insurance coverage; compliance with environmental laws and regulations; actions by governmental or regulatory agencies, including changes in tax laws; the failure to qualify as a mutual fund trust; Pengrowth's ability to access external sources of debt and equity capital; the impact of foreign and domestic government programs; the occurrence of unexpected events involved in the operation and development of oil and gas properties; the Company being unable to sell assets and monetize sufficient hedges to avoid covenant breaches and the Company being unable to negotiate covenant relaxation and the potential for breaching a covenant. Further information regarding these factors may be found under the heading "Business Risks" in the MD&A and under "Risk Factors" in the AIF.

The foregoing list of factors that may affect future results is not exhaustive. When relying on our forward-looking statements to make decisions, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Furthermore, the forward-looking statements contained in this press release are made as of the date of this press release, and Pengrowth does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable laws.

The forward-looking statements contained in this press release are expressly qualified by this cautionary statement

Wassem Khalil Manager, Investor Relations (403) 233-0224 or Toll free 1-855-336-8814
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Amplifon Data Breach Spurs Legal Scrutiny for Millions

Updated Category News Views 446

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 56

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 344

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 250

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 333

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading
LG's ASIL D Certification: A Game Changer in Autos

Updated Category News Views 38

Why LG's ASIL D Certification Matters There ain't much in the tangled mess of automotive innovations these days that'll make a seasoned investor raise an eyebrow, but here comes LG Electronics grabbing the ASIL D certification like it's a badge of market honor. The ISO 26262 ASIL D is no walk in the park, folks—it's the top rung on the safety ladder, something that's...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 90

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading
Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 245

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
FFR's OmniMind Takes Top Spot In RoboColiseum Rankings

Updated Category News Views 104

The AI Race Heats Up with FFR's Big Win Stop the presses—FFR's OmniMind AI just snagged the top spot on RoboColiseum's global rankings. Yeah, you heard right, this ain't just some run-of-the-mill news. As of November 6, they've parked themselves in pole position, beating out heavyweights like NVIDIA's GR00T N1.7 and GPT-6 Astra. That's like hitting a grand slam right...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 612

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading

Top 5 Most Recently Viewed Articles

SOCi's AI Marketing: Leading G2's Summer 2026 Rankings

Updated Category News Views 12

AI's Rising Star in Enterprise Marketing Here's a tidbit worth chewing over your morning coffee: SOCi Inc., a name that's been buzzing in the enterprise circles, has nailed top spots in G2's Summer 2026 Report. We're talking about leading the charge in AI marketing and localized visibility, territories tough to crack unless you've got serious chops. In a world where...

Continue Reading
AI and the Future of Staffing: A Market Growth Story

Updated Category News Views 344

AI and the Future of Staffing: A Growth Story The staffing services market is on the verge of a major transformation, thanks in large part to advancements in Artificial Intelligence (AI). This evolution is projected to add an astounding USD 236.6 billion to the global staffing services market between 2024 and 2028. During this time, the market is expected to experience a...

Continue Reading
Optical Innovations Unite: OCC and Lightera's New Partnership

Updated Category News Views 317

Strategic Collaboration Between OCC and Lightera Optical Cable Corporation (NASDAQ: OCC) and Lightera, LLC are entering a significant partnership aimed at enhancing their product offerings primarily in the data center and enterprise sectors. This collaboration builds upon their long-term relationship, combining their strengths to create innovative optical connectivity...

Continue Reading
INFINOX Welcomes Artem Gonov as New Chief Technology Officer

Updated Category News Views 148

INFINOX Appoints Artem Gonov as Chief Technology Officer INFINOX, a globally recognized brokerage, has recently appointed Artem Gonov as its new Chief Technology Officer (CTO). This strategic move underlines the company's commitment to enhancing its technology landscape and providing exceptional platforms for its clients. Artem Gonov's Background and Expertise Mr. Gonov...

Continue Reading
George Medicines’ GMRx2 Sets New Standard for Hypertension Care

Updated Category News Views 126

George Medicines Introduces GMRx2 for Hypertension Management Recent findings published in The Lancet highlighted the promising results of a Phase III trial for GMRx2, a novel triple combination pill aimed at managing hypertension. Developed by George Medicines, this medication is making waves in the field of cardiovascular care as it demonstrates significant advancements...

Continue Reading